[BioS] HLB, After FDA Approval of 'Rifitu,' Announces Group Mid-to-Long-Term Strategy
High impactPredicted impact: High· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
FDA approval of Rifitu drug, a major regulatory ruling; large for a ₩5.4T company.
Knock-on:HLB Life ScienceMoves with HLB (corr 0.90); moved with HLB on 17 of its 18 biggest daysHLB PharmaceuticalMoves with HLB (corr 0.87); moved with HLB on 15 of its 16 biggest days